CME Group Inc. will announce earnings for the fourth quarter and full year of 2025 before the markets open on Wednesday, February 4, 2026.Written highlights for the quarter will be posted on the company's website at 6:00 a.m. Central Time, the same time it provides its earnings press release.The company will also hold an investor […]

Norda Stelo unveils its 2025 Impact Report, a detailed analysis of its achievements in sustainability, responsible governance, and innovation applied to consulting-engineering. In a context where climate transition, infrastructure pressures, and evolving societal expectations are profoundly transforming the industry, the firm confirms its position as a leading player in sustainable engineering. As the first major

Dublin, Ireland, Dec. 17, 2025 (GLOBE NEWSWIRE) — In an era of surging demand for futuristic technologies and digital currencies, Xeronum is born. Xeronum is an up-and-coming cryptocurrency and utility layer designed to streamline payments, loyalty, and rewards across travel, leisure, and creator-focused platforms–delivering speed, transparency, and scalability from day one. The idea took shape

(NASDAQ:CYTK), Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on Net Sales in Greater China SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO(R) (aficamten) has been approved by the China National Medical Products Administration (NMPA)

(NASDAQ:ELAB), Phase III is intended to generate meaningful biological data on potential drug compounds prioritized by YuvaBio's classifier, which applies proprietary machine-learning methods to identify candidates targeting muscle preservation through improvements in mitochondrial function. Experimental work designed to identify candidates that may upregulate ANT1, a key gene involved in metabolic function and muscle integrity. Phase

(NASDAQ:BENF), DALLAS, Dec. 17, 2025 (GLOBE NEWSWIRE) — Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets, today announced that its Board of Directors (the “Board”) has appointed Peter T. Cangany Jr. as Chairman of the

(NasdaqGM:NKLR), NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) — Terra Innovatum Global N.V. (“Terra Innovatum” or the “Company“) (NASDAQ: NKLR), a developer of micro-modular nuclear reactors today announced continued substantive progress in the licensing of its SOLO(TM) Micro-Modular Reactor (MMR) through active engagement with the U.S. Nuclear Regulatory Commission (NRC), reinforcing the company's position at

(NasdaqGM:HBIO), Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial Flexibility BroadOak Partner Bill Snider to Join Board of Directors and Company to Form Advisory Board on Growth and Operating Opportunities HOLLISTON, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), today announced it

(NasdaqGM:ACRV), WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) — Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed

(TSX:BBD-A),(TSX:BBD-B),(OTC US:BDRBF),(Other OTC:BDRBF), MONTREAL, Dec. 17, 2025 (GLOBE NEWSWIRE) — Bombardier today confirmed the company is on track to reach its previously stated net leverage ratio target of 2.0-2.5x. With the $500 million debt redemption notice announced on December 17, which is expected to close by Feb 17, 2026, the Bombardier team will have successfully